sample 4

Our strong track record of success is hinged on the talent and dedication of the entrepreneurs with whom we partner. Their vision and dedication help to build companies into global successes.

What Starfish-backed entrepreneurs say about us:

"Starfish Ventures' investment in DesignCrowd has been game-changing.  The injection of capital has supercharged our business and the support from the Starfish team has been outstanding.  Post-investment, Starfish have added great value to our board, provided introductions in Silicon Valley and helped us complete our first acquisition.  I highly recommend Starfish Ventures and its exceptional team." Alec Lynch, DesignCrowd

“Neuprotect received funding from Starfish Ventures’ Pre-Seed fund in 2004 and a follow-on investment from STF II in 2011. Michael and Nick have been an invaluable support to us, providing expert guidance through the maze of possible commercialisation routes. Their expertise came to the fore when we designed the killer experiments to show proof of concept and subsequently sought co-investors. They have a broad knowledge base and deep scientific expertise, coupled with multiple VC connections in Australia and the US.  Michael and Nick were pivotal in us securing further investment from AstraZeneca’s VC arm, and we’re now in a preclinical development program.” – Grant McLachlan, Neuprotect 

"When we met Michael and John, we had a working prototype but were unclear on how to take our medical device to a commercial and international medical standard. John and Michael worked with us closely to develop a strategic plan to move to this stage. We especially recognise the team’s ability to highlight and explain unfamiliar legal and financial points and key areas to improve upon – their experience in this area was incredible. Additionally, Starfish’s incubator space has allowed us to grow from a two person team to ten. We’ve seen other life science start ups join and grow too big for the space – having the attention of the team next door has meant that we’re looking at doing the same in the next 18 months or so.” - Andrew Ronchi, dorsaVi